Glioma Cancer
It is well known that Gliomas are amongst the most destructive types of cancers out there. Unfortunately, Gliomas are the most frequent tumors in the central nervous system accounting “for more than 32% of all primary brain and CNS tumors and 80% of all malignancies of the brain and CNS”. Tons of research has been done in this topic with a variety of different methods, however, it still has a poor prognosis with frequent recurrences. The gold standard so far to treat this type of tumors has been surgery, radiotherapy, and chemotherapy. However, a huge dilemma many practitioners face while treating this type of tumors is the blood brain barrier that acts a shield for this tumors and restricts the delivery of therapeutic molecules into the brain.
…show more content…
It is still not precisely known how this process is carried out and most only have an idea of how the process is carried out, along with other underlying limitations. For example, according to Fang Zhang, a researcher who did an extensive review of new innovative mechanisms in order to treat glioma tumors, “the lack of specific target may disperse the drug transportation into the brain and increase peripheral side effects.” Furthermore, since CPP’s are very diverse it is difficult to clearly analyze what mechanism of this molecules are involved in the delivery of the peptide molecules. For instance, a huge downside to using CPP’s since they are very complex is that they can initiate an immune response. Although the peptide can be tested prior to the administration, since every individual is different it will lead to different reactions depending on the individual. Therefore, is extremely important not to generalize and treat each case individually. Lastly another way CPPS are limited is that although not a factor in vitro, in vivo application certain enzymes present in the cells can denature the peptides. Currently there is limited research that has been done in humans but in theory this could be a huge breakthrough in the field. Moreover, what many of these initial studies show that CPPs along with other approaches that increase the blood brain barrier permeability are highly innovative and show promise for future human
It is still not precisely known how this process is carried out and most only have an idea of how the process is carried out, along with other underlying limitations. For example, according to Fang Zhang, a researcher who did an extensive review of new innovative mechanisms in order to treat glioma tumors, “the lack of specific target may disperse the drug transportation into the brain and increase peripheral side effects.” Furthermore, since CPP’s are very diverse it is difficult to clearly analyze what mechanism of this molecules are involved in the delivery of the peptide molecules. For instance, a huge downside to using CPP’s since they are very complex is that they can initiate an immune response. Although the peptide can be tested prior to the administration, since every individual is different it will lead to different reactions depending on the individual. Therefore, is extremely important not to generalize and treat each case individually. Lastly another way CPPS are limited is that although not a factor in vitro, in vivo application certain enzymes present in the cells can denature the peptides. Currently there is limited research that has been done in humans but in theory this could be a huge breakthrough in the field. Moreover, what many of these initial studies show that CPPs along with other approaches that increase the blood brain barrier permeability are highly innovative and show promise for future human